{"id":"https://openalex.org/W4400935004","doi":"https://doi.org/10.1080/14737167.2024.2382976","title":"Cost-effectiveness of dapagliflozin plus standard treatment compared to standard therapy for the management of chronic kidney disease in Colombia","display_name":"Cost-effectiveness of dapagliflozin plus standard treatment compared to standard therapy for the management of chronic kidney disease in Colombia","publication_year":2024,"publication_date":"2024-07-24","ids":{"openalex":"https://openalex.org/W4400935004","doi":"https://doi.org/10.1080/14737167.2024.2382976","pmid":"https://pubmed.ncbi.nlm.nih.gov/39045630"},"language":"en","primary_location":{"id":"doi:10.1080/14737167.2024.2382976","doi":"https://doi.org/10.1080/14737167.2024.2382976","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1080/14737167.2024.2382976","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/14737167.2024.2382976?needAccess=true","source":{"id":"https://openalex.org/S98544388","display_name":"Expert Review of Pharmacoeconomics & Outcomes Research","issn_l":"1473-7167","issn":["1473-7167","1744-8379"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Pharmacoeconomics & Outcomes Research","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://www.tandfonline.com/doi/pdf/10.1080/14737167.2024.2382976?needAccess=true","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5042476100","display_name":"Pieralessandro Lasalvia","orcid":"https://orcid.org/0000-0002-8998-6608","observed_orcids":["https://orcid.org/0000-0002-8998-6608"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Pieralessandro Lasalvia","raw_affiliation_strings":["Departamento econom\u00eda de la salud, Neuroeconomix, Bogot\u00e1, Colombia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departamento econom\u00eda de la salud, Neuroeconomix, Bogot\u00e1, Colombia","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109751790","display_name":"Eliana C. V\u00e1squez M.","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eliana C. V\u00e1squez M.","raw_affiliation_strings":["Departamento econom\u00eda de la salud, Neuroeconomix, Bogot\u00e1, Colombia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departamento econom\u00eda de la salud, Neuroeconomix, Bogot\u00e1, Colombia","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Jose Javier Arango \u00c1lvarez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405285604","display_name":"Asociaci\u00f3n Colombiana de Medicina Interna","ror":"https://ror.org/05rnq2307","country_code":"CO","type":"nonprofit","lineage":["https://openalex.org/I4405285604"]}],"countries":["CO"],"is_corresponding":false,"raw_author_name":"Jose Javier Arango \u00c1lvarez","raw_affiliation_strings":["M\u00e9dico Internista \u2013 Nefr\u00f3logo. Presidente ACMI (Asociaci\u00f3n Colombiana Medicina Interna), Bogot\u00e1, Colombia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"M\u00e9dico Internista \u2013 Nefr\u00f3logo. Presidente ACMI (Asociaci\u00f3n Colombiana Medicina Interna), Bogot\u00e1, Colombia","institution_ids":["https://openalex.org/I4405285604"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5081702065","display_name":"Paola Garc\u00eda","orcid":"https://orcid.org/0000-0001-9852-749X","observed_orcids":["https://orcid.org/0000-0001-9852-749X"]},"institutions":[{"id":"https://openalex.org/I233745408","display_name":"Pontificia Universidad Javeriana","ror":"https://ror.org/03etyjw28","country_code":"CO","type":"education","lineage":["https://openalex.org/I233745408"]},{"id":"https://openalex.org/I4210153247","display_name":"Hospital Universitario San Ignacio","ror":"https://ror.org/052d0td05","country_code":"CO","type":"healthcare","lineage":["https://openalex.org/I4210153247"]}],"countries":["CO"],"is_corresponding":false,"raw_author_name":"Paola Garcia-Padilla","raw_affiliation_strings":["Nefr\u00f3loga, Pontificia Universidad Javeriana \u2013 Hospital Universitario San Ignacio, Bogot\u00e1, Colombia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nefr\u00f3loga, Pontificia Universidad Javeriana \u2013 Hospital Universitario San Ignacio, Bogot\u00e1, Colombia","institution_ids":["https://openalex.org/I233745408","https://openalex.org/I4210153247"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5042476100"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.5551,"has_fulltext":true,"cited_by_count":2,"citation_normalized_percentile":{"value":0.6744233,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":95,"max":96},"biblio":{"volume":"24","issue":"10","first_page":"1133","last_page":"1143"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.8970000147819519,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.8970000147819519,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10408","display_name":"Chronic Kidney Disease and Diabetes","score":0.07169999927282333,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.01489999983459711,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dapagliflozin","display_name":"dapagliflozin","score":1.0},{"id":"https://openalex.org/keywords/chronic-kidney-disease","display_name":"chronic kidney disease","score":0.9850000143051147},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9710000157356262},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.8930000066757202},{"id":"https://openalex.org/keywords/dapa-ckd-trial","display_name":"DAPA-CKD trial","score":0.9300000071525574},{"id":"https://openalex.org/keywords/heart-failure-hospitalization","display_name":"heart failure hospitalization","score":0.8289999961853027},{"id":"https://openalex.org/keywords/cardiovascular-mortality","display_name":"cardiovascular mortality","score":0.9990000128746033},{"id":"https://openalex.org/keywords/renal-mortality","display_name":"renal mortality","score":0.38600000739097595},{"id":"https://openalex.org/keywords/colombian-health-system","display_name":"Colombian health system","score":0.6389999985694885},{"id":"https://openalex.org/keywords/willingness-to-pay-threshold","display_name":"willingness-to-pay threshold","score":0.8709999918937683},{"id":"https://openalex.org/keywords/markov-model","display_name":"Markov model","score":0.7620000243186951}],"concepts":[{"id":"https://openalex.org/C2777422806","wikidata":"https://www.wikidata.org/wiki/Q409898","display_name":"Dapagliflozin","level":4,"score":0.929612398147583},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8016258478164673},{"id":"https://openalex.org/C2778653478","wikidata":"https://www.wikidata.org/wiki/Q1054718","display_name":"Kidney disease","level":2,"score":0.7963926792144775},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.62198406457901},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.46925923228263855},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.43849003314971924},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.42998769879341125},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4290471374988556},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.12469092011451721},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.12195250391960144},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.08894672989845276},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.08370408415794373},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.058941781520843506}],"mesh":[{"descriptor_ui":"D000077203","descriptor_name":"Sodium-Glucose Transporter 2 Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000077203","descriptor_name":"Sodium-Glucose Transporter 2 Inhibitors","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D000077203","descriptor_name":"Sodium-Glucose Transporter 2 Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001559","descriptor_name":"Benzhydryl Compounds","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D001559","descriptor_name":"Benzhydryl Compounds","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D001559","descriptor_name":"Benzhydryl Compounds","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D003105","descriptor_name":"Colombia","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006333","descriptor_name":"Heart Failure","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D006333","descriptor_name":"Heart Failure","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D006760","descriptor_name":"Hospitalization","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D006760","descriptor_name":"Hospitalization","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008390","descriptor_name":"Markov Chains","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D018450","descriptor_name":"Disease Progression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D018803","descriptor_name":"Models, Economic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051436","descriptor_name":"Renal Insufficiency, Chronic","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1080/14737167.2024.2382976","doi":"https://doi.org/10.1080/14737167.2024.2382976","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1080/14737167.2024.2382976","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/14737167.2024.2382976?needAccess=true","source":{"id":"https://openalex.org/S98544388","display_name":"Expert Review of Pharmacoeconomics & Outcomes Research","issn_l":"1473-7167","issn":["1473-7167","1744-8379"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Pharmacoeconomics & Outcomes Research","raw_type":"journal-article"},{"id":"pmid:39045630","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/39045630","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert review of pharmacoeconomics & outcomes research","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1080/14737167.2024.2382976","doi":"https://doi.org/10.1080/14737167.2024.2382976","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1080/14737167.2024.2382976","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/14737167.2024.2382976?needAccess=true","source":{"id":"https://openalex.org/S98544388","display_name":"Expert Review of Pharmacoeconomics & Outcomes Research","issn_l":"1473-7167","issn":["1473-7167","1744-8379"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Pharmacoeconomics & Outcomes Research","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9907000064849854,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4400935004.pdf","grobid_xml":"https://content.openalex.org/works/W4400935004.grobid-xml"},"referenced_works_count":19,"referenced_works":["https://openalex.org/W1982967337","https://openalex.org/W1994222210","https://openalex.org/W2003281337","https://openalex.org/W2013564592","https://openalex.org/W2113778938","https://openalex.org/W2167436480","https://openalex.org/W2523134289","https://openalex.org/W2559986308","https://openalex.org/W2626446274","https://openalex.org/W2977682063","https://openalex.org/W2978315525","https://openalex.org/W3014210594","https://openalex.org/W3088173406","https://openalex.org/W3154427929","https://openalex.org/W3188274764","https://openalex.org/W4206672182","https://openalex.org/W4210822121","https://openalex.org/W4211136945","https://openalex.org/W4238030285"],"related_works":["https://openalex.org/W7220739190","https://openalex.org/W4405514629","https://openalex.org/W4308060342","https://openalex.org/W4210822121","https://openalex.org/W3208505308","https://openalex.org/W4392503097","https://openalex.org/W7221168940","https://openalex.org/W4206672182","https://openalex.org/W4294879033","https://openalex.org/W7167713909"],"abstract_inverted_index":{"BACKGROUND:":[0],"The":[1,67],"DAPA-CKD":[2,60],"study":[3,132],"showed":[4,133],"that":[5,134],"dapagliflozin":[6,34],"added":[7],"to":[8,27,63],"standard":[9,36,39,96,139,144],"treatment":[10,37,40,97,145],"reduced":[11],"the":[12,31,47,59,64,108,111,127],"risk":[13],"of":[14,33],"chronic":[15,43,79],"kidney":[16,44,80],"disease":[17,45,81],"progression,":[18],"and":[19,35,75,78],"death":[20],"from":[21],"renal":[22],"or":[23],"cardiovascular":[24,76],"causes":[25],"compared":[26],"placebo.":[28],"OBJECTIVE:":[29],"Assess":[30],"cost-effectiveness":[32],"versus":[38],"alone":[41],"for":[42,71],"within":[46],"Colombian":[48,65],"health":[49],"system.":[50],"METHODS:":[51],"We":[52],"employed":[53],"a":[54,84,88,99],"Markov":[55],"model":[56,68],"based":[57],"on":[58],"study,":[61],"tailored":[62],"scenario.":[66],"forecasted":[69],"hospitalizations":[70],"heart":[72],"failure,":[73],"overall":[74],"mortality,":[77],"progression":[82],"over":[83],"10-year":[85],"horizon":[86],"with":[87,95,138,148],"5%":[89],"discount":[90],"rate.":[91],"RESULTS:":[92],"Dapagliflozin":[93],"combined":[94,137],"is":[98,141],"cost-effective":[100,142],"intervention":[101],"in":[102,126],"treating":[103],"stage":[104],"2-4":[105],"CKD.":[106],"In":[107],"base":[109],"case,":[110],"ICER":[112],"was":[113,124],"US":[114],"$5,366,":[115],"below":[116],"1":[117],"GDP":[118],"(US":[119],"$6.558)":[120],"per":[121],"capita.":[122],"This":[123],"consistent":[125],"sensitivity":[128],"analyses.":[129],"CONCLUSION:":[130],"Our":[131],"dapagliflozin,":[135],"when":[136],"treatment,":[140],"against":[143],"alone,":[146],"aligning":[147],"Colombia's":[149],"willingness-to-pay":[150],"threshold.":[151]},"counts_by_year":[{"year":2026,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2024-07-25T00:00:00"}